The 2012 Nobel Prize in Chemistry has been awarded to Brian K. Kobilka and Robert J. Lefkowitz for their studies of G-protein-coupled receptors. Their pioneering work over the past 40 years has provided detailed molecular insight into the structure and function of this fundamentally important family of receptors.
The Early Years of GPCR Biochemistry
The idea of receptors began in the early 20th century, and it was J.N. Langley who first raised the concept of a ''receptive substance'' on cells to explain the ability of drugs to regulate neuromuscular transmission. As late as 1973, however, several noted pharmacologists such as Ahlquist and Sutherland remained skeptical as to whether such receptors actually existed as distinct entities. During this period of skepticism, Robert Lefkowitz became interested in receptor biology, and this interest would drive his entire scientific career. Lefkowitz received his MD from Columbia in 1966; subsequently moved to the NIH to train with Jesse Roth and Ira Pastan and then to Mass General, where he worked with Ed Haber; and also received residency training in cardiology. During this training period, Lefkowitz developed one of the first radioligand binding assays for a G-protein-coupled receptor (GPCR), the adrenocorticotropic hormone (ACTH) receptor, in the Pastan and Roth labs and also studied the binding of catecholamines to cardiac tissue with Haber. Lefkowitz moved to Duke University in 1973 to take his first faculty position. There, together with one of his first trainees and now long-time colleague Marc Caron, as well as other trainees in the lab, he set about developing the biochemical techniques needed to study b-adrenergic receptors (bARs). His rationale at the time for studying the bAR was that it was of physiological importance to cardiovascular function, it activated the enzyme adenylyl cyclase, and there were many bAR agonists and antagonists available to facilitate biochemical analysis of the receptor.
This early work included the development of a specific radioligand binding assay to enable the measurement of bAR-binding sites in cells and tissues (Lefkowitz et al., 1974) , the identification of detergents to successfully solubilize a functional bAR from membrane preparations (Caron and Lefkowitz, 1976) , and the synthesis of an affinity resin and photoaffinity ligands to facilitate receptor purification (Caron et al., 1979) . The development of these techniques enabled the subsequent purification of the b 2 AR initially from frog erythrocytes in 1981 and then from mammalian sources such as hamster lung. Moreover, comparable techniques were developed in the Lefkowitz lab for purification of the other three then known adrenergic receptor subtypes (b 1 AR, a 1 AR, and a 2 AR). It is important to note that these receptors are found at exceedingly low levels in most tissues and required 100,000-fold purification to fully isolate. Subsequent studies reconstituted the purified b 2 AR into phospholipid vesicles and provided the first demonstration that the isolated receptor could effectively couple agonist binding to activation of the heterotrimeric G protein Gs and subsequent activation of adenylyl cyclase to produce cAMP (Cerione et al., 1984) . Another important application of the ligand binding methods led to the development of the ''ternary complex model,'' which proposed that high-affinity agonist binding was the result of an agonist-receptor-G-protein complex-results beautifully visualized 30 years later by the agonist-b 2 AR-Gs structure from the Kobilka lab. Thus, the early work of Lefkowitz laid the groundwork for the biochemical characterization of GPCRs and demonstrated that the b 2 AR exists as a distinct protein entity that binds ligands and couples ligand binding to activation of heterotrimeric G proteins.
Cloning Reveals a Family of GPCRs
The stage for the cloning of the b 2 AR and other adrenergic receptors was largely set by the focus of the Lefkowitz group on receptor purification. The purified hamster b 2 AR ultimately provided the first sequence of several peptides that were then used to synthesize oligonucleotides for cloning studies. Importantly, this work involved collaboration between the Lefkowitz group and a group from Merck Sharp & Dohme, with initial cloning efforts being coordinated by Richard Dixon at Merck. Brian Kobilka, a cardiology fellow who joined the Lefkowitz lab in 1984, was also involved in this project, and when cDNA library screening proved unsuccessful, he decided to generate a hamster genomic library. Subsequent screening of this library by Kobilka and Dixon ultimately yielded the gene encoding the b 2 AR, which was then used to isolate a b 2 AR cDNA (Dixon et al., 1986 ). There were two surprising features of the b 2 AR gene. First, the gene was intronless. At the time, this was somewhat heretical, although this has proven to be a common feature of many GPCR genes. Second, and even more surprising, was that the amino acid sequence of the b 2 AR had significant homology with rhodopsin, the receptor for light that had been independently sequenced by the Ovchinikov and Hargrave groups in 1982 and cloned by Nathans and Hogness in 1983. This finding provided the first insight that rhodopsin and the b 2 AR were members of a family of GPCRs that would likely have similar structures. Indeed, as noted by the authors in their publication, ''the amino-acid sequence predicted for the bAR indicates significant amino-acid homology with bovine rhodopsin and suggests that, like rhodopsin, bAR possesses multiple membranespanning regions'' (Dixon et al., 1986) . Though this finding makes sense in retrospect, no one at that time had envisioned that visual and hormonal receptors would have any homology. This discovery was confirmed several months later by Ross and Ulrich, who cloned a cDNA for the avian b 1 AR, and by Numa and coworkers, who cloned the gene for a porcine muscarinic acetylcholine receptor. Moreover, the Lefkowitz group also went on to rapidly clone additional GPCRs, including seven of the remaining eight adrenergic receptors, as well as the 5HT 1A receptor. Kobilka played a major role in cloning five of these receptors and also developed a novel b 2 AR/a 2 AR chimeric receptor approach to start to dissect the domains involved in ligand binding and G protein coupling (Kobilka et al., 1988) . Taken together, this body of work provided the first fundamental insight into the structural similarities in the superfamily of GPCRs, which now numbers 800 in humans.
Regulation of GPCR Function
Another major area of investigation in the Lefkowitz lab during the 1980s focused on understanding the mechanisms involved in receptor desensitization. This line of investigation was being carried out simultaneously with the receptor purification and cloning efforts and demonstrated that the b 2 AR underwent rapid agonist-promoted phosphorylation and internalization. These studies also led to the surprising revelation that the structural similarities observed between the b 2 AR and rhodopsin also extended to the mechanisms that regulate the signaling of these two receptors. The first insight into this similarity was provided by the identification of a protein kinase called the b-adrenergic receptor kinase (now known as GRK2), which was found to phosphorylate the b 2 AR in an agonistdependent manner ). This observation was strikingly similar to the phosphorylation of lightactivated rhodopsin by the enzyme rhodopsin kinase (now known as GRK1), which had been previously identified. Indeed, additional studies demonstrated that each kinase could phosphorylate each other's preferred substrate, albeit to a significantly reduced extent (e.g., GRK2 preferred the b 2 AR over rhodopsin, whereas GRK1 preferred rhodopsin over the b 2 AR). The subsequent cloning of GRK2 revealed it to be the first cloned member of a family of kinases that now numbers seven (Benovic et al., 1989) . Another striking similarity observed by the Lefkowitz group between the regulation of visual and hormonal signaling involved the role of the protein arrestin. Arrestin was initially identified as a protein in rod cells that could bind to activated phosphorylated rhodopsin and effectively quench phototransduction. Initial studies on the b 2 AR suggested the involvement of an arrestin-like protein in the desensitization process, and subsequent cloning efforts identified a nonvisual arrestin termed b-arrestin (Lohse et al., 1990) . Thus, these studies revealed significant conservation in the mechanisms that regulate visual and hormonal signaling.
Understanding the mechanisms involved in regulating GPCR signaling has remained a major focus of the Lefkowitz group over the past 20-25 years. Their work has provided important mechanistic understanding into the dynamics of GRK and b-arrestin function, with a major current emphasis involving the development of biased agonists that have the ability to promote selective interaction of a given GPCR with G proteins, GRKs, or b-arrestins (Whalen et al., 2011) . This line of investigation has the promise to lead to the development of improved GPCR therapeutics with reduced side effects.
GPCR Structure
In 1989, toward the end of the GPCR cloning efforts in the Lefkowitz lab, Kobilka moved to Stanford University. He initially focused his research efforts in two major areas. One involved developing knockout mice to better understand the physiological role of the adrenergic receptors, and the other involved the use of biophysical strategies to better understand the structural dynamics of the b 2 AR, with an ultimate goal of crystallizing the receptor. Although significant insight was gained from the biophysical work in the Kobilka lab, it was Palczewski and coworkers who provided the first glimpse of a GPCR structure by solving the X-ray crystal structure of rhodopsin at 2.8 Å resolution (Palczewski et al., 2000) . This work not only provided important insight into the structure of rhodopsin in its basal state but also clearly proved that such complex membrane proteins could be crystallized. At this point, the Kobilka group had been working on developing methods to crystallize the b 2 AR for some 10 years and had made significant progress but had no crystals in hand. The major approaches being used to facilitate crystallization included alanine scanning mutagenesis for thermostabilization, use of inverse agonists to stabilize the protein in a basal state analogous to rhodopsin, and the development of antibody fragments that could bind to the intracellular domains of the receptor and help stabilize the conformation. These strategies, in combination with lipid-mediated screening and the use of microfocus diffraction techniques, ultimately contributed to the first reported X-ray structure of the b 2 AR . This 3.4 Å resolution structure provided insight into the transmembrane domains and intracellular portions of the receptor, although the extracellular regions were not visible. Another approach being used by the Kobilka group involved engineering lysozyme into the third intracellular loop of the receptor . This strategy ultimately resulted in a 2.4 Å high resolution structure of the b 2 AR that was published 1 week after the initial Rasmussen work (Chezerov et al., 2007) . Indeed, the engineering of lysozyme into GPCRs has proven to be a panacea for crystallizing and solving GPCR structures. Another key ingredient in solving these initial structures involved the collaborations that Kobilka developed with outstanding crystallographers, including Ray Stevens at Scripps, Bill Weis at Stanford, and Gebhard Schertler at the MRC Laboratory of Molecular Biology. Kobilka and Weis have now teamed up to solve the structures of many GPCRs, including the agonist-bound b 2 AR, a nanobody-bound b 2 AR in an active conformation, the M2 and M3 muscarinic acetylcholine receptors, and the m-and d-opioid receptors. The Stevens group has also solved many additional GPCR structures, including the A2A adenosine, CXCR4, D3 dopamine, H1 histamine, sphingosine 1-phosphate, and kopioid. Solving GPCR crystal structures seems almost routine now, though the 15 years that it took Kobilka to obtain the initial X-ray structure of the b 2 AR was a true test of perseverance.
Although the successful crystallography of GPCRs over the past 5 years has been a stunning achievement, what proved to be the icing on the cake was the elegant structure of an agonistb 2 AR-Gs complex reported by Rasmussen, Sunahara, Kobilka, and coworkers in 2011 (Rasmussen et al., 2011) (Figure 1) . Indeed, the press release for the 2012 Nobel Prize in Chemistry ended with the statement, ''Kobilka and his research team captured an image of the b-adrenergic receptor at the exact moment that it is activated by a hormone and sends a signal into the cell. This image is a molecular masterpiece-the result of decades of research.'' The pioneering work of the Lefkowitz and Kobilka laboratories over the past 40 years has provided a tremendous understanding of how this fundamentally important family of receptors function and is indeed a molecular masterpiece. 
